CYPHERPUNK TECHNOLOGIES INC.

CYPHSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1509745

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	$1.5M	$1.5M	$1.5M
Research and Development Expense	$73.2M	$45.0M	$32.2M	$20.4M	$24.4M
Operating Expenses	$87.0M	$56.8M	$42.9M	$30.0M	$33.5M
Operating Income (Loss)	-$87.0M	-$56.8M	-$41.4M	-$28.5M	-$33.5M
Interest Expense	—	$54.0K	$41.0K	$39.0K	$23.0K
Other Nonoperating Income (Expense)	—	—	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$81.4M	-$54.4M	-$40.6M	-$27.5M	-$32.9M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$72.8M	$70.4M	$117.9M	$54.4M	$7.4M
Assets, Current	$71.6M	$68.0M	$116.9M	$52.3M	$4.2M
Cash and Cash Equivalents, at Carrying Value	$70.6M	$65.5M	$114.9M	$52.1M	$3.9M
Liabilities	—	$11.5M	$10.0M	$7.7M	$9.2M
Liabilities, Current	$12.7M	$11.2M	$10.0M	$7.4M	$8.5M
Accounts Payable, Current	$6.5M	$5.7M	$4.2M	$2.7M	$4.6M
Stockholders' Equity Attributable to Parent	$58.9M	$107.9M	$46.7M	-$1.7M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$43.8M	-$49.0M	-$35.2M	-$26.0M	-$26.9M
Net Cash Provided by (Used in) Investing Activities	$49.0M	$49.0M	—	$25.0K	-$85.0K
Net Cash Provided by (Used in) Financing Activities	-$30.0K	-$210.0K	$98.0M	$74.0M	$14.8M
Payments to Acquire Property, Plant, and Equipment	—	—	—	—	$100.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)